Health Care [ 3/12 ] | Health Care Equipment & Supplies [ 22/74 ]
NASDAQ | Common Stock
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.
Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.
The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014.
Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -0.16 Increased by +69.81% | -0.44 Increased by +63.64% |
| Aug 14, 23 | -0.42 Increased by +2.33% | -0.42 |
| May 15, 23 | 0.27 Increased by +145.76% | -0.49 Increased by +155.10% |
| Mar 31, 23 | -0.53 Decreased by -17.78% | -0.48 Decreased by -10.42% |
| Nov 14, 22 | -0.53 Decreased by -8.16% | -0.58 Increased by +8.62% |
| Aug 15, 22 | -0.43 Decreased by -19.44% | -0.60 Increased by +28.33% |
| May 11, 22 | -0.59 Decreased by -1.72% | -0.55 Decreased by -7.27% |
| Mar 31, 22 | -0.45 Increased by +47.67% | -0.60 Increased by +25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.92 M Increased by +61.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.14 M Decreased by -25.16% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 5.64 M Increased by +N/A% | 2.82 M Increased by +150.04% | Increased by +50.04% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -7.43 M Decreased by -73.99% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -5.02 M Decreased by -8.37% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -4.11 M Decreased by -21.13% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -5.64 M Decreased by -3.28% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -4.27 M Increased by +46.63% | Decreased by N/A% Decreased by N/A% |